Journal
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
Volume 6, Issue 4, Pages 543-550Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ECI.10.30
Keywords
biological therapy; Crohn's disease; drug delivery/targeting; gene therapy/delivery; inflammatory bowel disease; microcarriers; molecular biopharmaceutics; nanocarriers; transgenic bacteria; ulcerative colitis
Categories
Ask authors/readers for more resources
The therapeutic management of inflammatory bowel disease (IBD) represents the perfect scenario for drug targeting to the site(s) of action. While existing formulation-based targeting strategies include rectal dosage forms and oral systems that target the colon by pH-, time-, microflora- and pressure-triggered drug release, novel approaches for site-specific delivery in IBD therapy will target the inflamed intestine per se rather than intestinal region. The purpose of this article is to present a mechanistic update on the strategies employed to achieve minimal systemic exposure accompanied by maximal drug levels in the inflamed intestinal tissue. The introduction of biological agents, micro/nanoparticulate carriers including liposomes, transgenic bacteria, and gene therapy opportunities are discussed, as well as the challenges remaining to be achieved in the targeted treatment of IBD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available